JP2018537087A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537087A5
JP2018537087A5 JP2018524747A JP2018524747A JP2018537087A5 JP 2018537087 A5 JP2018537087 A5 JP 2018537087A5 JP 2018524747 A JP2018524747 A JP 2018524747A JP 2018524747 A JP2018524747 A JP 2018524747A JP 2018537087 A5 JP2018537087 A5 JP 2018537087A5
Authority
JP
Japan
Prior art keywords
polynucleotide
seq
nucleotide sequence
factor viii
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018524747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537087A (ja
JP6768798B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/061684 external-priority patent/WO2017083762A1/en
Publication of JP2018537087A publication Critical patent/JP2018537087A/ja
Publication of JP2018537087A5 publication Critical patent/JP2018537087A5/ja
Application granted granted Critical
Publication of JP6768798B2 publication Critical patent/JP6768798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018524747A 2015-11-13 2016-11-11 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター Active JP6768798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255317P 2015-11-13 2015-11-13
US62/255,317 2015-11-13
PCT/US2016/061684 WO2017083762A1 (en) 2015-11-13 2016-11-11 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020132079A Division JP7069258B2 (ja) 2015-11-13 2020-08-04 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター

Publications (3)

Publication Number Publication Date
JP2018537087A JP2018537087A (ja) 2018-12-20
JP2018537087A5 true JP2018537087A5 (enExample) 2019-12-12
JP6768798B2 JP6768798B2 (ja) 2020-10-14

Family

ID=57539605

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018524747A Active JP6768798B2 (ja) 2015-11-13 2016-11-11 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
JP2020132079A Active JP7069258B2 (ja) 2015-11-13 2020-08-04 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
JP2022075864A Active JP7307836B2 (ja) 2015-11-13 2022-05-02 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
JP2023108132A Active JP7631425B2 (ja) 2015-11-13 2023-06-30 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020132079A Active JP7069258B2 (ja) 2015-11-13 2020-08-04 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
JP2022075864A Active JP7307836B2 (ja) 2015-11-13 2022-05-02 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
JP2023108132A Active JP7631425B2 (ja) 2015-11-13 2023-06-30 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター

Country Status (18)

Country Link
US (4) US10189888B2 (enExample)
EP (1) EP3374387A1 (enExample)
JP (4) JP6768798B2 (enExample)
KR (2) KR20230008256A (enExample)
CN (3) CN116949052A (enExample)
AU (4) AU2016353353B2 (enExample)
BR (1) BR112018009717B1 (enExample)
CA (1) CA3005334A1 (enExample)
CL (1) CL2018001299A1 (enExample)
CO (1) CO2018005377A2 (enExample)
EA (2) EA038288B1 (enExample)
IL (3) IL305526A (enExample)
MX (1) MX2018005982A (enExample)
MY (2) MY190067A (enExample)
SG (2) SG11201804070XA (enExample)
TW (3) TW202302627A (enExample)
WO (1) WO2017083762A1 (enExample)
ZA (3) ZA201803443B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102766526B1 (ko) 2015-10-28 2025-02-13 상가모 테라퓨틱스, 인코포레이티드 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3374388A1 (en) 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2017180861A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsulvania Gene therapy for treating hemophilia b
WO2017180857A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia a
IL266264B2 (en) 2016-11-04 2023-11-01 Baxalta Inc Adeno-associated virus formulations
AU2018338608B2 (en) * 2017-09-27 2025-09-11 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
MA49923A (fr) * 2017-10-02 2020-06-24 Res Inst Nationwide Childrens Hospital Système de déciblage de miarn pour interférence spécifique d'un tissu
KR102105145B1 (ko) * 2017-10-13 2020-05-13 영남대학교 산학협력단 촬영 장치 및 용기
KR101952102B1 (ko) * 2017-12-07 2019-02-26 주식회사 지앤피바이오사이언스 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터
AU2019306194A1 (en) * 2018-07-16 2021-02-04 Baxalta GmbH Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
JP7684212B2 (ja) * 2018-08-03 2025-05-27 サンガモ セラピューティクス, インコーポレイテッド 第viii因子の発現による改善された臨床パラメーター
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2020168362A1 (en) 2019-02-15 2020-08-20 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
JP7585217B2 (ja) * 2019-06-05 2024-11-18 クリスパー セラピューティクス アクチェンゲゼルシャフト 改善された第viii因子発現による血友病aのための遺伝子編集
US20200405883A1 (en) * 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
US20220396610A1 (en) * 2019-11-01 2022-12-15 Freeline Therapeutics Limited Factor viii polypeptide
US20230023826A1 (en) * 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
KR102817222B1 (ko) * 2021-04-02 2025-06-11 연세대학교 산학협력단 Fe-fviii 변이 유전자로 교정된 줄기세포, 이로부터 분화된 내피 세포 및 이를 포함하는 혈우병 예방 또는 치료용 약제학적 조성물
KR102421131B1 (ko) * 2021-05-28 2022-07-15 알엔에이진(주) 세포내에서 장시간동안 존재할 수 있는 외부 도입 mRNA를 선별하는 방법
US20240254197A1 (en) * 2021-11-25 2024-08-01 Sichuan Real&Best Biotech Co., Ltd. Engineered Human FVIII with Enhanced Secretion Ability and Clotting Activity
US20250282847A1 (en) * 2022-04-28 2025-09-11 Joint Stock Company "Biocad" Codon-optimized nucleic acid encoding the fviii-bdd
CN115948408A (zh) * 2022-09-23 2023-04-11 上海信致医药科技有限公司 改进的人凝血因子viii基因表达盒及其应用
TW202435846A (zh) 2023-03-14 2024-09-16 美商希吉隆醫療公司 包含共價交聯多醣及胰島細胞之水膠膠囊
WO2025008774A1 (en) * 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2025180508A1 (en) * 2024-02-29 2025-09-04 Shanghai Vitalgen Biopharma Co., Ltd. Human factor viii variant expression cassettes and uses thereof for treating hemophilia a

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
ATE322547T1 (de) 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
CN1179976C (zh) * 2000-12-29 2004-12-15 中国科学院上海生物化学研究所 产生凝血因子ⅷ的生产方法和宿主细胞
CA2461443C (en) 2001-10-05 2011-07-12 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2003052051A2 (en) 2001-12-17 2003-06-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
JP4644663B2 (ja) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
KR100959454B1 (ko) 2007-12-10 2010-05-25 주식회사 동부하이텍 반도체 소자 및 그 제조 방법
DK2282764T3 (da) 2008-04-22 2019-10-14 Vib Vzw Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
JP5770161B2 (ja) 2009-04-06 2015-08-26 ノヴォ ノルディスク アー/エス 血小板への第viii因子タンパク質の標的送達
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
BR112014017111A8 (pt) * 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
CN111499761A (zh) * 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123503A1 (en) 2012-02-17 2013-08-22 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
DK2956477T4 (da) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
SG10201803999UA (en) 2013-03-15 2018-06-28 Bayer Healthcare Llc Recombinant factor viii formulations
US20160102133A1 (en) 2013-06-24 2016-04-14 Weidong Xiao Mutant factor viii compositions and methods
ES2813698T3 (es) 2013-09-12 2021-03-24 Biomarin Pharm Inc Vectores de AAV que comprenden un gen que codifica el factor VIII
AU2015301598B2 (en) 2014-08-13 2020-07-16 Liron Elkouby An improved expression cassette for packaging and expression of variant Factor VIII for the treatment of hemostasis disorders
AU2016215124B2 (en) * 2015-02-06 2020-08-06 The University Of North Carolina At Chapel Hill Optimized human clotting Factor VIII gene expression cassettes and their use
JP6879486B2 (ja) 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel Fviiiおよびfix用の最適化された肝臓特異的発現系
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Similar Documents

Publication Publication Date Title
JP2018537087A5 (enExample)
JP2023115348A5 (enExample)
JP2018537089A5 (enExample)
JP2020520662A5 (enExample)
JP2019506166A5 (enExample)
JP2019122392A5 (enExample)
JP2017018125A5 (enExample)
FI3889173T3 (fi) Optimoitu tekijä viii:n geeni
JP2011004753A5 (enExample)
JP2013027391A5 (enExample)
JP2018138049A5 (enExample)
JP2009515529A5 (enExample)
JP2020531032A5 (enExample)
JP2017532966A5 (enExample)
JP2004512020A5 (enExample)
JP2019514361A5 (enExample)
JP2017521074A5 (enExample)
JP2017504354A5 (enExample)
JP2012082206A5 (enExample)
JP2005120106A5 (enExample)
JP2020518268A5 (enExample)
JP2010110330A5 (enExample)
JP2016501535A5 (enExample)
JP2015521465A5 (enExample)
JP2014507146A5 (enExample)